Laboratorios HIPRA SA

DUBLIN, Oct. 24, 2023 /PRNewswire/ -- The "Veterinary Vaccines Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering. The global veterinary vaccines market, with a market size of US$12.4 billion in 2022, is poised for significant growth, with an anticipated market size of US$21.5 billion by 2028. This growth is expected to be characterized by a robust compound annual growth rate (CAGR) of 9.3% during the forecast period spanning from 2023 to 2028. Market Overview: Veterinary vaccines are bio-prepared immunizations administered to domestic and wild animals through parenteral and oral routes to stimulate protective immune responses without causing the diseases themselves. These vaccines play a crucial role in reducing animal suffering, enhancing immune efficiency, and preventing the development and transmission of various contagious zoonotic diseases. They are cost-effective, reliable, and offer long-term prevention, making them essential for both companion and livestock animals worldwide. Market Trends and Drivers: Several key factors are driving the growth of the global veterinary vaccines market: Rising Demand for Effective Immunization: Increasing demand for effective immunization products, especially with the domestication of companion and livestock animals, is a key driver. Prevalence of Infectious Epizootic Disorders: The rising prevalence of infectious epizootic disorders is leading to greater demand for vaccines to protect animal health. Government Investments: Governments are investing significantly in the pharmaceutical sector to enhance veterinary vaccine manufacturing procedures. Innovation in Vaccine Technology: The introduction of DNA and RNA vaccines with improved stability, efficacy, and administration approaches is contributing to market growth. Needle-Free Vaccine Injections: Innovative intramuscular needle-free vaccine injections are gaining popularity due to their enhanced safety and less painful administration. Protection of Livestock-Based Products: Veterinary vaccines are needed to prevent disease transmission from livestock-based products like milk, meat, and eggs. Healthcare Infrastructure Improvement: Improvements in healthcare infrastructure and ongoing R&D activities are fueling market growth. Market Segmentation: The veterinary vaccines market is segmented based on various factors: By Vaccine Type: Livestock Vaccines Bovine Vaccines Poultry Vaccines Porcine Vaccines Others Companion Animal Vaccines Canine Vaccines Feline Vaccines Equine Vaccines By Technology: Attenuated Live Vaccines Inactivated Vaccines Toxoid Vaccines Recombinant Vaccines Others By Route of Administration: Subcutaneous Intramuscular Intranasal By Distribution Channel: Veterinary Hospitals Veterinary Clinics Pharmacies and Drug Stores Others By Region: North America United States Canada Asia Pacific China Japan India South Korea Australia Indonesia Others Europe Germany France United Kingdom Italy Spain Russia Others Latin America Brazil Mexico Others Middle East and Africa Competitive Landscape: Key players in the global veterinary vaccines market include Boehringer Ingelheim International GmbH, Ceva Sante Animale, Elanco Animal Health Incorporated, Hester Biosciences Limited, HIPRA, Indian Immunologicals Limited, Merck & Co. Inc., Neogen Corporation, Phibro Animal Health Corporation, Virbac SA, Zoetis Inc., and others. For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Phalguni Deswal @Phalguni_GD The approval for Hipra’s Covid-19 vaccine was based on an immunobridging study comparing the efficacy of Bimervax with Pfizer and BioNTech’s mRNA vaccine, Comirnaty. Image Credit: Ansty / Shutterstock. Accord Healthcare has announced an exclusive commercialisation agreement for a Covid-19 vaccine manufactured by Spanish biotech Hipra in the UK. Bimervax is a bivalent recombinant protein vaccine based on alpha and beta variants of SARS-CoV-2. Recommended Reports Reports LOA and PTSR Model - pneumococcal (24-valent) vaccine GlobalData Reports LOA and PTSR Model - Herpes Zoster Vaccine in Herpes Zoster (Shingles) GlobalData View all Companies Intelligence Pfizer Inc Hera SpA Moderna Inc BioNTech SE Novavax Inc View all It was authorised by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) as a booster vaccine that provides active immunisation against Covid-19 in people aged 16 years and older on 31 July 2023. It is also authorised for use in the European Union (EU). However, this marketing agreement comes after a recent EMA decision to seek Covid-19 vaccines that specifically target the SARS-CoV-2 XBB 1.5 Omicron subvariant. Hipra has an existing contract, announced in 2022, with the Health Emergency Preparedness and Response Authority ( Hera ) of the European Commission (EC) for Bimervax. The agreement allows for the procurement of 250 million doses of the vaccine. The approval for Hipra’s Covid-19 vaccine was based on an immunobridging study comparing the efficacy of Bimervax with Pfizer and BioNTech ’s mRNA vaccine, Comirnaty. In the press release , Hipra managing director Carles Fàbrega said: “The Hipra Covid-19 vaccine is the first human health vaccine to be designed, developed and fully manufactured in Spain. “Having the structures and capabilities ranging from the most basic research and development to the production of vaccines in the country is a key factor in being able to support a rapid response in the event of future health emergencies and reinforces the strategic autonomy of Europe in the field of health.” Last month, the European Medicines Agency (EMA) recently granted full approval for Novavax ’s Matrix-M adjuvant protein-based Covid-19 vaccine (Nuvaxovid). The vaccine is approved as a primary vaccine for people 12 years of age and older and as a booster dose for adults aged 18 and older. Moderna has filed for EMA approval for a modified version of its mRNA vaccine based on a SARS-CoV-2 variant.

The Medicines and Healthcare products Regulatory Agency (MRHA) has authorised HIPRA Human Health’s COVID-19 vaccine, Bimervax, after it met the regulator’s required safety, quality and effectiveness standards. HIPRA, a biotech company that provides vaccines and diagnostic services, developed Bimervax, which combines part of the SARS-CoV-2 virus spike protein with an additional ingredient designed to trigger a stronger immune response, known as an adjuvant. The new COVID-19 vaccine will be given as a booster injection to eligible individuals aged 16 years and over. The regulator’s decision was based on data from a study of 765 adults who received primary vaccination with two doses of the Comirnaty COVID-19 vaccine and then a booster dose of either Bimervax or Comirnaty. Bimervax showed a strong immune response, and common side effects were mild and self-resolved within a few days of vaccination. The MRHA’s authorisation comes less than a month after HIPRA said it would be initiating a clinical trial to evaluate the safety and immune response of Bimervax when co-administered with the seasonal influenza vaccine. The study, which will involve 300 adults aged 65 or older who were first vaccinated against COVID-19 with an mRNA vaccine, has been authorised by the Spanish Agency for Medicines and Health Products and will last two months. Bimervax is now the ninth COVID-19 vaccine to be authorised by the MRHA. The MRHA authorised SK Chemicals’s SKYCovion earlier this year for use as a primary vaccination in those aged 18 and over, making it the eighth COVID-19 vaccine to be approved by the regulator. Its decision was based on data from two clinical trials of approximately 3,100 individuals between the ages of 18 and 84. SKYCovion demonstrated a strong immune response, with only mild common side effects that resolved on their own soon after vaccination.